Study evaluation of 2nd hormone line response by -[18F]fluoro-17ß-œstradiol (FES) PET/CT in metastatic breast cancer patients
Phase 1
- Conditions
- Therapeutic area: Diseases [C] - Cancer [C04]MedDRA version: 19.0Level: LLTClassification code 10007305Term: Carcinoma breastSystem Organ Class: 100000004864
- Registration Number
- EUCTR2016-002120-83-FR
- Lead Sponsor
- INSTITUT DE CANCEROLOGIE DE L'OUEST RENE GAUDUCHEA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 30
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 30
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method